Last reviewed · How we verify
Frenolone (METOFENAZATE)
Frenolone (generic name: METOFENAZATE) is a drug. It is currently in Phase 2 development.
Frenolone works by binding to specific proteins or receptors in the body to produce a therapeutic effect.
Frenolone, also known as Metofenazate, is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it is not FDA approved for any indications. As a small molecule, it is likely to work by interacting with specific biological molecules to produce a therapeutic effect. However, without more information, it is difficult to provide a comprehensive summary of its use and safety considerations. Further research is needed to determine its potential as a therapeutic agent.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | METOFENAZATE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like locks, and Frenolone is a key that fits into those locks. When it binds to the right lock, it can turn on or off certain cellular processes to help treat a disease or condition. This is a simplified way of understanding how small molecule drugs like Frenolone work at a molecular level.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Frenolone CI brief — competitive landscape report
- Frenolone updates RSS · CI watch RSS
Frequently asked questions about Frenolone
What is Frenolone?
How does Frenolone work?
What is the generic name of Frenolone?
What development phase is Frenolone in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing